INTRODUCTION {#s1}
============

Advanced lung cancer (LC) is a leading cause of cancer deaths worldwide \[[@R1]--[@R4]\]. Nearly 95% of all lung cancers are either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). Current treatments include a combination of traditional surgical interventions and adjunctive radiation and chemotherapy. Molecularly targeted drugs for LC include epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) like gefitinib, erlotinib, and afatinib \[[@R5]--[@R9]\], and anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKI) like crizotinib \[[@R10]\]. However, the overall long-term survival rate from lung cancer is extremely low \[[@R11]--[@R14]\]. Despite advanced technology, nearly 50% of lung cancer patients are diagnosed at an advanced stage \[[@R4]\]. Thus, better understanding of the lung cancer pathogenesis and development of effective molecular and cellular biomarkers \[[@R4]\] are necessary to detect cancer early and improve therapeutic outcomes \[[@R15]--[@R17]\]. The development of serum biomarkers like microparticles would be useful to predict prognostic outcomes in LC \[[@R18]--[@R21]\].

Microparticles (MPs) or membrane-bound vesicles are small fragments of the plasma membrane released by activated and/or apoptotic cells. The MPs ranging from 0.1 to 1.0μm in size circulate in blood and other body fluids and are known to mediate inflammation and thrombosis \[[@R22]--[@R31]\]. Additionally, MPs have differential effects on angiogenesis depending on their origin \[[@R22], [@R26], [@R28]--[@R31]\]. Microparticles from platelets promote capillary network formation and production of pro-angiogenic factors \[[@R22], [@R24], [@R28], [@R30], [@R32]\]. In contrast, both endothelial- and lymphocyte-derived MPs possess either pro- or anti-angiogenic properties depending on the stimuli \[[@R28], [@R29]\].

Circulating MPs are also associated with a wide range of diseases including LC \[[@R28], [@R32]--[@R39]\]. Circulating endothelial-derived activated MPs (EDAc-MPs) were useful in predicting 1-year morality in advanced stage NSCLC patients \[[@R20]\]. However, since majority of the patients had received palliative treatment prior to enrolment in our previous study, the PDAp-MPs (platelet-derived apoptotic MPs), PDAc-MPs (platelet-derived activated MPs), and EDAp-MPs (endothelial-derived apoptotic MPs) were not prognostic \[[@R20]\]. Therefore, we conducted this prospective study by measuring the circulating levels of MPs in advanced stage NSCLC patients to analyze their prognostic outcomes in advanced stage NSCLC patients.

RESULTS {#s2}
=======

Baseline circulating levels of four types microparticles in study subjects {#s2_1}
--------------------------------------------------------------------------

The circulating levels of the PDAc-MPs, PDAp-MPs, EDAc-MPs and EDAp-MPs were significantly higher in advanced NSCLC patients compared to control subjects. This suggested that the circulating MPs are useful diagnostic biomarkers for advanced NSCLC patients (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}).

###### Comparison of circulating levels of four types microparticles between lung cancer patients and healthy control group

  Variables   Study Group (n=136)\*   Control Group (n=25)   P-value
  ----------- ----------------------- ---------------------- ---------
  PDAc-MPs    184866.40 ± 723526.40   20334.75 ± 25884.62    0.009
  PDAp-MPs    30988.10 ± 95402.90     13725.08 ± 5401.12     0.038
  EDAc-MPs    7196.16 ± 33141.41      598.54 ± 582.43        0.022
  EDAp-MPs    27171.17 ± 105285.34    5486.17 ± 4331.44      0.018

Data are expressed as mean ± SD.

PDAc-MPs = platelet-derived activated microparticles; PDAp-MPs = platelet-derived apoptotic MPs; EDAc-MPs = endothelial-derived activated MPs; EDAp-MPs = endothelial-derived apoptotic MPs.

\* indicated the blood sample was drawn prior to treatment.

![Comparison of baseline levels of circulating microparticles in the study and control subjects\
Circulating levels of **(A)** Platelet-derived activated MPs (PDAc-MPs; p = 0.009), **(B)** Platelet-derived apoptotic MPs (PDAp-MPs; p = 0.038), **(C)** Endothelial-derived activated MPs (EDAc-MPs; p = 0.022) and **(D)** Endothelial-derived apoptotic MPs (EDAp-MPs; p = 0.018) in study and control subjects. Note: CI = confidence intervals.](oncotarget-08-75952-g001){#F1}

Baseline characteristics of study patients {#s2_2}
------------------------------------------

The disease control (DC) and disease progression (DP) groups had similar parameters like gender, weight, height, surface area, mass index and incidence of smoking status. The serum levels of total cholesterol, sugar, glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) were also similar between these two groups. Furthermore, the red blood cell (RBC), white blood cell (WBC) and platelet counts as well as circulating levels of carcinoembryonic antigen (CEA) were also similar between the 2 groups. Furthermore, comorbidities like hypertension, diabetes mellitus, coronary artery disease and chronic obstructive lung disease were comparable between DC and DP groups (Table [2](#T2){ref-type="table"}).

###### Baseline Characteristics of 136 Study Patients

  Variable                             Disease Progression (n=42)   Disease Control (n=94)   P-value
  ------------------------------------ ---------------------------- ------------------------ ---------
  Age                                  62.69 ± 10.80                65.01 ± 10.23            0.244
  Sex (male)                           64.3% (27)                   61.7% (58)               0.849
  Body weight (kg)                     65.47 ± 19.72                73.04 ± 35.09            0.112
  Body height (cm)                     162.45 ± 23.02               147.34 ± 36.17           0.004
  Body surface area (m^2^)             1.67 ± 0.18                  1.64 ± 0.18              0.338
  Body mass index (kg/m^2^)            23.61 ± 3.27                 23.31 ± 3.66             0.642
  Smoking status                       50% (21)                     54.2% (51)               0.711
  Total cholesterol (mg/dL)            176.33 ± 49.09               182.25 ± 45.51           0.506
  Triglyceride (mg/dL)                 178.75±81.92                 193.12±86.47             0.365
  Ac sugar (mg/dL)                     123.17 ± 48.15               128.36 ± 66.16           0.608
  Creatinine                           0.90±0.34                    0.89±0.35                0.928
  Na                                   136.69±8.20                  137.10±6.91              0.766
  K                                    3.99±0.59                    3.85±0.57                0.224
  Aspartate aminotransferase (IU)      26.38 ± 16.36                25.62 ± 12.22            0.766
  Alanine aminotransferase (IU)        31.14 ± 38.10                28.79 ± 27.36            0.685
  White blood cell count (x10^3^/mL)   8.23±5.20                    7.92±3.48                0.690
  Red blood cell count (x10^6^/mL)     4.41±0.58                    4.44±0.73                0.814
  Platelet count (x10^3^/mL)           27.7±12.7                    26.4±10.5                0.539
  CEA                                  357.16±1760.44               75.88±166.13             0.302
  Underlying comorbidity                                                                     
   Hypertension                        47.6% (20)                   39.4% (37)               0.452
   Diabete mellitus                    19% (8)                      18.1% (17)               1.000
   COPD                                9.5% (4)                     12.1% (11)               1.000
   CAD                                 14.3% (6)                    22.3% (21)               0.355

Data are expressed as mean ± SD or % (n).

Lung cancer associated parameters in the study patients {#s2_3}
-------------------------------------------------------

The cell types of lung cancer (adenocarcinoma or non-adenocarcinoma) were similar between the DC and the DP groups. However, higher epidermal growth factor receptor (EGFR) mutation levels were observed in the DC patients compared to DP group. The incidence of metastasis and the metastatic sites were similar for the two groups of the patients. Also, the two groups showed no differences in stages IIIB or IV. However, the DP patients' performance status was poorer than the DC group, and the DC group of patients was easily met with target therapy (Table [3](#T3){ref-type="table"}).

###### Lung Cancer Associated Parameters in 136 Study Patients

  Variables                  Disease Progression (n=42)   Disease Control (n=94)   P-value
  -------------------------- ---------------------------- ------------------------ ---------
  Cell type                                                                        0.049
   Adenocarcinoma            73.8% (31)                   87.2% (82)               
   Non-adenocarcinoma        26.2% (11)                   12.8% (12)               
  Metastasis                                                                       0.355
   M0                        23.8% (10)                   21.3% (20)               
   M1a                       23.8% (10)                   36.2% (34)               
   M1b                       52.4% (22)                   42.5% (40)               
  Stage                                                                            0.824
   IIIb                      23.8% (10)                   21.3% (20)               
   IV                        76.2% (32)                   78.7% (74)               
  Metastatic site                                                                  
   Pleura                    31% (13)                     41.5% (39)               0.259
   Lung                      40.5% (17)                   26.6% (25)               0.440
   Bone                      28.6% (12)                   34% (32)                 0.559
   Liver                     7.1% (3)                     8.5% (8)                 1.000
   Adrenal gland             7.1% (3)                     1.1% (1)                 0.087
   Brain                     16.7% (7)                    12.8% (12)               0.596
  Performance status                                                               0.008
   0                         14.3% (6)                    9.6% (9)                 
   1                         57.1% (24)                   80.9% (76)               
   2                         28.6% (12)                   9.6% (9)                 
  Therapeutic Intervention                                                         0.000
   Target therapy            11.9% (5)                    70.2% (66)               
   Chemotherapy              88.1% (37)                   29.8% (28)               
  EGFR status                11.9% (5)                    70.2% (66)               0.000

Data are expressed as % (n).

Circulating microparticle levels in DC and DP patients {#s2_4}
------------------------------------------------------

Table [4](#T4){ref-type="table"} shows the changes in circulating levels of PDAc-MPs, PDAp-MPs, EDAc-MPs, EDAp-MPs between the DC and DP patients prior to and at the end of 1^st^ and 3^rd^ months after pharmacological intervention. The circulating levels of the four types of MPs were similar between the DC and DP groups prior to and at the end of the first month after pharmacological therapy (Figure [2](#F2){ref-type="fig"}). However, at the end of the third month after pharmacological therapy, all the four types of MPs were significantly lower in the DC group than in the DP group (Figure [2](#F2){ref-type="fig"}). This was corroborated by positive ΔEDAp-MP, ΔEDAc-MP, ΔPDAp-MP and ΔPDAc-MP values associated with DP. These findings demonstrated that the pharmacological therapy lowered the circulating MPs in the DC group (Table [4](#T4){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

###### Serial changes of circulating microparticles between disease progression and disease control patients

  Variables             Disease Progression (n=42)   Disease Control (n=94)   P-value
  --------------------- ---------------------------- ------------------------ ----------
  PDAc-MPs (time 1)\*                                                         0.554
  mean±SD               129713.69 ± 181619.98        209509.10 ± 862192.46    
  median                19720.5                      11749.5                  
  interquartile range   6978.75\~29012.25            7050.25\~18300           
  range                 3307\~408654                 399\~1172133             
  PDAp-MPs (time 1)\*                                                         0.963
  mean±SD               30424.81 ± 36668.18          31239.79 ± 112335.20     
  median                1290.0                       1432                     
  interquartile range   672.25\~3950                 603.5\~3220              
  range                 160\~92792                   70\~365091               
  EDAc-MPs (time 1)\*                                                         0.779
  mean±SD               5998.31 ± 15338.89           7731.37 ± 38596.88       
  median                20198.5                      15393                    
  interquartile range   8434.25\~38064               8244.25\~25611           
  range                 1042\~8637.5                 1165\~1097489            
  EDAp-MPs (time 1)\*                                                         0.816
  mean±SD               29695.21 ± 62524.79          26043.40 ± 119847.80     
  median                54283.5                      26465                    
  interquartile range   9166.75\~193062.75           12291.75\~69015.5        
  range                 1042\~863715                 66\~8264000              
  PDAc-MPs (time 2)†                                                          0.267
  mean±SD               61578.98 ± 83592.25          94027.07 ± 106312.33     
  median                10621                        11047                    
  interquartile range   7148.5\~14540                6145.75\~18297.5         
  range                 1818\~26138                  134\~46044               
  PDAp-MPs (time 2)†                                                          0.325
  mean±SD               15173.62 ± 11688.99          18028.77 ± 17020.22      
  median                763.5                        2240.5                   
  interquartile range   423.25\~1791.75              765\~4536.75             
  range                 104\~28217                   110\~21870               
  EDAc-MPs (time 2)†                                                          0.267
  mean±SD               2315.71 ± 4803.61            3237.34 ± 3474.93        
  median                11026                        12807.5                  
  interquartile range   7757.25\~20321               6660.25\~24240.25        
  range                 1239\~53748                  122\~10827               
  EDAp-MPs (time 2)†                                                          0.200
  mean±SD               10912.26 ± 5543.11           12782.32 ± 8648.35       
  median                35472                        61596.5                  
  interquartile range   8231.25\~76459.75            24945.5\~124349.5        
  range                 568\~425339                  48\~662081               
  PDAc-MPs (time 3)‡                                                          0.009
  mean±SD               163110.26 ± 250042.10        55555.49 ± 76172.00      
  median                16907                        8565.5                   
  interquartile range   10666.25\~25465.25           4527.75\~13739.75        
  range                 1050\~66499                  723\~45969               
  PDAp-MPs (time 3)‡                                                          0.013
  mean±SD               31602.12 ± 43567.74          13907.85 ± 13973.76      
  median                5121                         1158                     
  interquartile range   2212.5\~13313                518\~2915.25             
  range                 471\~127265                  99\~8049                 
  EDAc-MPs (time 3)‡                                                          0.007
  mean±SD               10551.19 ± 19882.08          1900.62 ± 1889.91        
  median                17211                        9094                     
  interquartile range   8945.75\~32166               5765.75\~16032.75        
  range                 1211\~206185                 966\~81818               
  EDAp-MPs (time 3)‡                                                          \<0.000
  mean±SD               19717.12 ± 13296.76          9966.81 ± 7436.74        
  median                110855.5                     27656.5                  
  interquartile range   492545\~221313.75            9829.5\~70369.5          
  range                 4831\~1499326                21\~465579               
  ΔEDAp-MPs                                                                   0.003
   Increase             64.3%(27)                    36.2%(34)                
   Decrease             35.7%(15)                    63.8%(60)                
  ΔEDAc-MPs                                                                   \<0.0001
   Increase             85.7%(36)                    44.7%(42)                
   Decrease             14.3%(6)                     55.6%(52)                
  ΔPDAp-MPs                                                                   0.036
   Increase             50%(21)                      30.9%(29)                
   Decrease             50%(21)                      69.1%(65)                
  ΔPDAc-MPs                                                                   0.005
   Increase             64.3%(27)                    37.2%(35)                
   Decrease             35.7%(15)                    62.8%(59)                

Data expressed as mean ± SD.

PDAc-MPs = platelet-derived activated microparticles; PDAp-MPs = platelet-derived apoptotic MPs; EDAc-MPs = endothelial-derived activated MPs; EDAp-MPs = endothelial-derived apoptotic MPs.

\* indicated the blood sampling was performed prior to any treatment. † indicated the blood sampling was performed at the end of 1^st^ month after pharmacological intervention. ‡ indicated the blood sample was performed at the end of the 3^rd^ month after pharmacological intervention.

ΔEDAp-MPs: EDApMPs levels that three months after treatment minus initial level

ΔEDAc-MPs: EDAcMPs levels that three months after treatment minus initial level

ΔPDAp-MPs: PDApMPs levels that three months after treatment minus initial level

ΔPDAc-MPs: PDAcMPs levels that three months after treatment minus initial level

![Comparison of changes in levels of the four types of microparticles in disease control (DC) and disease progression (DP) groups\
Changes in levels of **(A)** PDAc-MPs (p=0.027), **(B)** PDAp-MPs (p=0.015), **(C)** EDAc-MPs (p=0.007) and **(D)** EDAp-MPs (p=0.025) between DC and DP group of patients.](oncotarget-08-75952-g002){#F2}

Comparing effects of chemotherapy and targeted therapy on circulating microparticle levels {#s2_5}
------------------------------------------------------------------------------------------

Table [5](#T5){ref-type="table"} compares changes in circulating levels of PDAc-MPs, PDAp-MPs, EDAc-MPs, EDAp-MPs in the patients that received chemotherapy or targeted therapy. The lung cancer patients with EGFR mutant type were treated with EGFR TKI agents and those with EGFR wildtype subgroup were treated with chemotherapy based on guideline recommendations. The flow cytometric analysis showed that the circulating levels of the four types of MPs were similar between the chemotherapy and targeted therapy patients prior to and at the end of the first month after pharmacological therapy. However, at the end of the third month after pharmacological therapy, all the four types of MPs were significantly lower in patients that received targeted therapy compared to those that received chemotherapy. (Table [5](#T5){ref-type="table"})

###### Serial changes of circulating microparticles between chemotherapy and target therapy patients

  Variables             Chemotherapy (n=65)      Target therapy (n=71)   P-value
  --------------------- ------------------------ ----------------------- ---------
  PDAc-MPs (time 1)\*   223983.58 ± 1022792.58   149054.89 ± 224562.98   0.548
  PDAp-MPs (time 1)\*   44645.09 ± 136502.00     18485.23 ± 13633.03     0.129
  EDAc-MPs (time 1)\*   9618.75 ± 46275.14       9478.30 ± 12246.30      0.417
  EDAp-MPs (time 1)\*   42145.84 ± 15114.76      13461.90 ± 10052.02     0.132
  PDAc-MPs (time 2)†    73103.35 ± 109872.19     93987.94 ± 91086.41     0.228
  PDAp-MPs (time 2)†    16885.72 ± 17225.25      17386.25 ± 14031.42     0.852
  EDAc-MPs (time 2)†    2613.71 ± 4444.46        3263.08 ± 3412.56       0.339
  EDAp-MPs (time 2)†    11468.14 ± 7389.82       12879.21 ± 8241.49      0.297
  PDAc-MPs (time 3)‡    119051.69 ± 250550.43    61049.11 ± 83443.71     0.034
  PDAp-MPs (time 3)‡    24724.68 ± 36663.15      14472.15 ± 14869.75     0.039
  EDAc-MPs (time 3)‡    7070.12 ± 16525.59       2285.21 ± 2554.22       0.024
  EDAp-MPs (time 3)‡    15424.49 ± 12684.86      10738.13 ± 7661.49      0.011

Data expressed as mean ± SD.

PDAc-MPs = platelet-derived activated microparticles; PDAp-MPs = platelet-derived apoptotic MPs; EDAc-MPs = endothelial-derived activated MPs; EDAp-MPs = endothelial-derived apoptotic MPs.

\* indicated the blood sampling was performed prior to any treatment. † indicated the blood sampling was performed at the end of 1^st^ month after pharmacological intervention. ‡ indicated the blood sample was performed at the end of the 3^rd^ month after pharmacological intervention.

Circulating levels of microparticles in one-year survivors and non-survivors {#s2_6}
----------------------------------------------------------------------------

We observed that the four types of circulating MPs did not differ between 1-year survivors and non-survivors prior to and at one month time intervals after pharmacological intervention. However, at the end of the third month after pharmacological intervention, except for EDAc-MPs, the other three types of MPs were significantly higher in the one-year non-survivors than in one-year survivors. Additionally, PDAc-MPs and EDAc-MPs levels were significantly higher in 1-year non-survivors than in 1-year survivors. These findings suggest that the circulating MPs can serve as 1-year prognostic predictors in advanced stage NSCLC patients. (Table [6](#T6){ref-type="table"} and Figure [3](#F3){ref-type="fig"})

###### Serial changes of circulating microparticles between one year survivors and on year non-survivors

  Variables             One year non-survivors (n=34)   One year survivors (n=102)   P-value
  --------------------- ------------------------------- ---------------------------- ---------
  PDAc-MPs (time 1)\*   106012.59 ± 119401.35           211151.00 ± 832025.21        0.465
  PDAp-MPs (time 1)\*   22543.09 ± 19448.73             33803.11 ± 109590.41         0.553
  EDAc-MPs (time 1)\*   5019.29 ± 7981.37               7921.78 ± 38015.19           0.660
  EDAp-MPs (time 1)\*   29914.29 ± 68885.70             26256.79 ± 115164.17         0.862
  PDAc-MPs (time 2)†    86471.00 ± 96982.29             83184.78 ± 102325.18         0.334
  PDAp-MPs (time 2)†    14217.09 ± 9419.38              18123.68 ± 17079.45          0.486
  EDAc-MPs (time 2)†    3487.41 ± 5622.06               2774.49 ± 3205.34            0.098
  EDAp-MPs (time 2)†    11096.35 ± 5378.55              12574.28 ± 8505.54           0.870
  PDAc-MPs (time 3)‡    188877.00 ± 267863.35           55402.25 ± 78140.98          0.009
  PDAp-MPs (time 3)‡    23141.74 ± 38386.77             18115.76 ± 23505.10          0.007
  EDAc-MPs (time 3)‡    12522.74 ± 21674.66             1921.91 ± 1842.74            0.365
  EDAp-MPs (time 3)‡    17790.21 ± 12573.57             11373.84 ± 9379.33           0.007

Data expressed as mean ± SD.

PDAc-MPs = platelet-derived activated microparticles; PDAp-MPs = platelet-derived apoptotic MPs; EDAc-MPs = endothelial-derived activated MPs; EDAp-MPs = endothelial-derived apoptotic MPs.

\* indicated the blood sampling was performed prior to any treatment. † indicated the blood sampling was performed at the end of 1^st^ month after pharmacological intervention. ‡ indicated the blood sample was performed at the end of the 3^rd^ month after pharmacological intervention.

![Comparison of changes in levels of the four types of microparticles in one-year survivors and non-survivors\
Changes in levels of **(A)** PDAc-MPs (p=0.019), **(B)** PDAp-MPs (p=0.558), **(C)** EDAc-MPs (p=0.038), **(D)** EDAp-MPs (p=0.241 in one-year survivor and non-survivor groups.](oncotarget-08-75952-g003){#F3}

Receiver operating characteristic (ROC) plot of circulating levels of MPs and CEA in NSCLC patients with progressive and non-progressive disease {#s2_7}
------------------------------------------------------------------------------------------------------------------------------------------------

Next, we examined if the circulating levels of the four types of MPs and CEA could predict progressive disease in NSCLC patients. As shown in Figure [4](#F4){ref-type="fig"} and Table [7](#T7){ref-type="table"}, ROC curve analysis showed that the circulating levels of EDAp-MPs, EDAc-MPs, PDAp-MPs and PDAc-MPs were greater than 10468.5 counts/ml, 3557 counts/ml, 15055 counts/ml and 62700.5 counts/ml, respectively at the 3^rd^ month after therapy. These data showed that the 4 types of MPs had high sensitivity and specificity and were good prognostic predictors for advanced stage NSCLC. Further, multivariate logistic regression analysis showed that the EGFR mutant, levels of EDAc-MPs at 3^rd^ month after therapy and the ΔPDAp-MPs and ΔPDAc-MPs were independent prognostic predictors in NSCLC patients (Table [8](#T8){ref-type="table"}).

![Receiver operating characteristic (ROC) plot showing circulating levels of microparticles (MPs) in progressive and non-progressive NSCLC](oncotarget-08-75952-g004){#F4}

###### Value of four types of microparticles for predicting progressive disease of NSCLC patients

  Variables           AUC                 P value           95% CI
  ------------------- ------------------- ----------------- -----------------
  EDAp-MPs (time 3)   0.805               \<0.000           0.680\~0.861
  EDAc-MPs (time 3)   0.659               \<0.000           0.760\~0.907
  PDAp-MPs (time 3)   0.610               0.001             0.584\~0.787
  PDAc-MPs (time 3)   0.707               \<0.000           0.667\~0.847
  ΔEDAp-MPs           0.590               0.098             0.471\~0.708
  ΔEDAc-MPs           0.771               \<0.000           0.670\~0.872
  ΔPDAp-MPs           0.594               0.083             0.474\~0.714
  ΔPDAc-MPs           0.667               0.002             0.553\~0.781
  CEA                 0.460               0.464             0.354\~0.567
  **Variables**       **Cut-off value**   **Sensitivity**   **Specificity**
  EDAp-MPs (time 3)   10468.5             0.805             0.638
  EDAc-MPs (time 3)   3557                0.659             0.840
  PDAp-MPs (time 3)   15055               0.610             0.713
  PDAc-MPs (time 3)   62700.5             0.707             0.734
  ΔEDAp-MPs           +196                0.634             0.660
  ΔEDAc-MPs           +267                0.829             0.596
  ΔPDAp-MPs           +918.5              0.512             0.734
  ΔPDAc-MPs           +2448               0.634             0.670
  ΔCEA                +6.37               0.463             0.468

NSCLC = non small cell lung cancer; AUC = area under the curve; CI = confidence interval; NSCLC = non small cell lung cancer; PDAc-MPs = platelet-derived activated microparticles; PDAp-MPs = platelet-derived apoptotic microparticles; EDAc-MPs = endothelial derived activated microparticles; EDAp-MPs = endothelial-derived apoptotic microparticles.

ΔEDAp-MPs: EDApMPs levels that three months after treatment minus initial level

ΔEDAc-MPs: EDAcMPs levels that three months after treatment minus initial level

ΔPDAp-MPs: PDApMPs levels that three months after treatment minus initial level

ΔPDAc-MPs: PDAcMPs levels that three months after treatment minus initial level

###### Predictors of progressive disease in non-small cell lung cancer patients by multivariate logistic regression analysis

  Variable                   Comparison                        OR^b^ (95%CI^c^)           P-value
  -------------------------- --------------------------------- -------------------------- ----------
  Body height                Per 1 unit decrease               1.179(0.009\~1.387)        0.074
  Adrenal gland metastasis   Yes vs. No                        0.007(0.001\~69.783)       0.290
  CEA                        Disease control vs. Progression   0.999(0.998\~1.001)        0.464
  Performance status         2 vs. 0&1                         0.251(0.253\~1.193)        0.082
  EGFR mutant                Yes vs. No                        150.517(8.986\~2521.118)   \<0.0001
  EDAp-MPs (time3)           Per 1 unit decrease               1.000(1.000\~1.000)        0.412
  EDAc-MPs (time3)           Per 1 unit decrease               1.001(1.000\~1.002)        0.022
  PDAp-MPs (time3)           Per 1 unit decrease               1.000(1.000\~1.000)        0.327
  PDAc-MPs (time3)           Per 1 unit decrease               1.000(1.000\~1.000)        0.887
  ΔEDAp-MPs                  positive vs. negative             0.557(0.052\~6.004)        0.630
  ΔEDAc-MPs                  positive vs. negative             0.285(0.033\~2.468)        0.254
  ΔPDAp-MPs                  positive vs. negative             0.074(0.006\~0.892)        0.040
  ΔPDAc-MPs                  positive vs. negative             12.32(1.130\~134.32)       0.039

^a^ΔEDAp-MPs: EDApMPs levels that three months after treatment minus initial level

ΔEDAc-MPs: EDAcMPs levels that three months after treatment minus initial level

ΔPDAp-MPs: PDApMPs levels that three months after treatment minus initial level

ΔPDAc-MPs: PDAcMPs levels that three months after treatment minus initial level

^b^Odds ratio

^c^Confidence interval

DISCUSSION {#s3}
==========

In this study, we determined if circulating levels of MPs could predict clinical outcomes in advanced stage NSCLC patients. We observed that circulating levels of the four types of MPs that we analyzed were higher in advanced stage NSCLC patients. The levels of EDAc-MPs, EDAp-MPs, PDAc-MPs, PDAp-MPs did not differ between DC and DP prior to therapeutic intervention. However, by the end of the third month, all the four biomarkers were significantly lower in the DC group compared with the DP group and similar to control subjects. Additionally, the positive net changes of four types of microparticles (i.e., ΔEDAp-MPs, ΔEDAc-MPs, ΔPDAp-MPs and ΔPDAc-MPs) between 3^rd^ month and baseline were strongly associated with DP. Furthermore, ROC curve identified that the absolute values at three months and the relative changes of MP values over time (i.e., ΔEDAp-MPs, ΔEDAc-MPs, ΔPDAp-MPs and ΔPDAc-MPs) had notably higher sensitivity and specificity than that of the CEA level for predicting the prognostic outcomes. Moreover, multivariate logistic regression analysis exhibited that the EGFR mutant, EDAc-MPs level at 3^rd^ month and the net change between baseline and 3^rd^ month (i.e., ΔPDAp-MPs and ΔPDAc-MPs) were also independently predictive of DP in NSCLC patients. Accordingly, these suggested that these four types of circulating MPs may be useful biomarkers for predicting prognostic outcomes in LC patients.

This study also showed that the circulating levels EDAc-MPs, EDAp-MPs, PDAc-MPs were higher in study patients prior to receiving treatment than in control subjects and were consistent with previous studies \[[@R18]--[@R20]\]. Most importantly, the circulating levels of the four types of MPs in the DC group were significantly lower and comparable to the control subjects at end of the third month in the DC group than in the DP group. Furthermore, the circulating levels of MPs independently predicted the one-year prognostic clinical outcome in the advanced stage NSCLC patients. Thus, our findings highlight that serial measurement of circulating MPs can predict therapeutic response and prognostic outcomes in advanced NSCLC patients, especially when considering the cost and effectiveness of target therapy.

An association between aberrant EGFR mutation activity and better prognostic outcomes has been reported previously \[[@R40]\] \[[@R18]--[@R20]\]. Additionally, poor performance status and poorer prognostic outcomes were associated according to previous studies \[[@R41]\] \[[@R18]--[@R20]\]. We demonstrated that the poor performance status was significantly higher in the DP group, whereas EGFR mutations were significantly lower in the DP group.

This study has limitations. First, the sample size of this cohort study was relatively small. Therefore, a new clinical trial with larger sample size is needed to validate that circulating MP levels can predict long-term clinical outcomes in advanced NSCLC patients. Second, this study measured only advanced NSCLC patients. Therefore, the usefulness of these four biomarkers in small cell lung cancer or other types of cancer patients is not known.

In conclusion, we demonstrated that serial measurement of the circulating levels of EDAc-MPs, EDAp-MPs, PDAc-MPs, PDAp-MPs predicted prognostic outcomes in advanced NSCLC patients.

MATERIALS AND METHODS {#s4}
=====================

NSCLC patient enrollment and therapeutic strategies {#s4_1}
---------------------------------------------------

Patient enrollment, data collection, classification of advanced stage NSCLC and therapeutic strategies were according to our previous studies \[[@R18]--[@R20]\]. We assessed images and pathological findings of all patients who received evaluation or treatment for LC at Kaohsiung Chang Gung Memorial Hospital. We determined the eligibility of patients for interventions including surgery, adjunctive or palliative chemotherapy, irradiation therapy and/or target therapy based on the AJCC cancer staging criteria, 7^th^ edition \[[@R39]\]. Based on the radiological findings, we categorized LC patients into stages I, II, IIIA, IIIB, and IV according to AJCC cancer staging criteria, 7^th^ edition \[[@R42]\]. Patients with stage IIIB or stage IV NSCLC were categorized as advanced stage NSCLC. All the patients were enrolled for further evaluation, blood sampling and treatment in the outpatient department or upon hospital admission.

Detailed in-hospital and follow-up data including age, gender, chest x-ray findings, computed tomography, fibro-bronchoscopic findings, bone scans or ultrasound studies, other image findings, histological, pathological and laboratory findings were collected prospectively and entered into a computer database for analyses.

Informed consent was obtained from all patients and control subjects enrolled in the study. The study protocol was approved by the Institutional Review Committee on Human Research at Kaohsiung Chang Gung Memorial Hospital (IRB number: 100-1024B). The clinical investigations were conducted according to the principles outlined in the Declaration of Helsinki.

To circumvent adverse influences on measurement of circulating level of MPs, patients with one or more of the following criteria were excluded based on our previous studies \[[@R18]--[@R20]\]: (1) recent surgery or trauma during the preceding 2 months;(2) refusal to participate in the study; (3) other co-existent or history of malignances; (4) severe organ disease other than LC like chronic kidney disease (CKD \> stage III), liver cirrhosis, hematologic disorders, congestive heart failure; (5) current use of anti-platelet agents;(6) history of febrile disorders; (7) acute or chronic inflammatory disease other than LC during the study period; or (8) a history of autoimmune diseases with or without immunosuppressive therapy.

A total of 1418 NSCLC patients were screened at Kaohsiung Chang Gung Memorial Hospital from March 2012 to January 2015. Among them, 1106 (78%) were advanced NSCLC patients. For the purpose of the study, only patients with advanced NSCLC without prior treatment were considered. Among the 1,418 patients (including NSCLC and other type of lung cancer), 1145 patients did not fit the enrolment criteria and were excluded from the study. Additionally, 35 patients were excluded due to the aforementioned reasons. Finally, 136 patients who were diagnosed with advanced stage NSCLC between March 2012 and January 2015 were prospectively enrolled in this study \[stage IIIB, 22.1% (30); stage IV, 77.9% (106)\] (Table [3](#T3){ref-type="table"}). These 136 patients were further divided into disease controlled (DC) group (n=94) and disease progression (DP) group (n=42).

Flow cytometry analysis of circulating microparticles {#s4_2}
-----------------------------------------------------

As shown in Figure [5](#F5){ref-type="fig"}, the circulating MPs were categorized as (1) platelet-derived activated MPs (PDAc-MPs; CD31^+^ CD42b^+^ AN^-^V^-^); (2) platelet-derived apoptotic MPs (PDAp-MPs; CD31^+^ CD42b^+^ AN^-^V^+^); (3) endothelial-derived activated MPs (EDAc-MPs; CD31^+^ CD42b^-^ AN^-^V^-^); and (4) endothelial-derived apoptotic MPs (EDAp-MPs; CD31^+^ CD42b^-^ AN^-^V^+^) based on a previous study \[[@R43]\] with some modifications \[[@R18]--[@R20]\].

![Flow cytometric analysis\
Representative FACS plots showing the four different types of microparticles.](oncotarget-08-75952-g005){#F5}

Blood sample collection and processing {#s4_3}
--------------------------------------

To determine circulating levels of MPs in advanced stage NSCLC patients, blood samples were collected at 9:00 am prior to and at the end of the first and third month after therapeutic interventions according to previously published protocol \[[@R18]--[@R20]\]. Additionally, blood samples were also collected at 9:00 am once from control subjects.

For flow cytometry, peripheral blood was collected in acid citrate dextrose (ACD) vacutainer tubes. Platelet-rich plasma was prepared by centrifuging 1.5ml peripheral blood at 2500 g at 4°C for 15 min without acceleration. Then, 250μl plasma samples were thawed and centrifuged at 19,800 g for 10 min at 4°C, and then collected for analyzing MPs smaller than 1.0μm.

Size calibration was conducted with 1.0μm beads (Invitrogen, Carlsbad, CA). The MP pellet was re-suspended with 150μl of AnnexinV binding buffer (BD Biosciences). All buffers were sterile-filtered with a 0.2μm filter. Then, 100μl MPs were incubated in a TruCOUNT tube (BD Biosciences) with the following fluorescent monoclonal antibodies: (1) phycoerythrin (PE)-conjugated anti-CD31 (BD Biosciences); (2) fluorescein isothiocyanate--conjugated anti-AnnexinV (BD Biosciences) and; (3) phycoerythrin-Cy5 (PE-Cy5)-conjugated anti-CD42b (BD Biosciences). The samples were incubated in the dark for 15 min at room temperature followed by addition of 400μl AnnexinV binding buffer and then analyzed in a FC500 flow cytometer (Beckman Coulter). The absolute count of MPs was measured by setting up the FACS machine with TruCount beads at 10,000 events. Additionally, white blood cell (WBC) counts, biochemistry and electrolyte levels were analyzed by standard laboratory methods in our hospital.

Disease classification {#s4_4}
----------------------

Change in tumor burden was assessed to determine tumor response to adjunctive therapy \[[@R18]--[@R20]\]. The chest computed tomography (CT) scans were routinely performed at baseline and at 12 week intervals after adjunctive therapy to determine the status of the disease. The tumor measurement was based on the current guidelines of Response Evaluation Criteria in Solid Tumors (RECIST) including complete response, partial response, stable disease and progressive disease \[[@R39]\]. Accordingly, we categorized the disease status as disease-controlled (DC) or disease-progressed (DP). The DC status was determined at the 3rd month after the treatment and defined as disease with regression with complete response, partial response or stable disease. On the other hand, the DP was defined as disease unresponsive to therapy with a growing tumor or metastasis after complete course of treatment. To elucidate if the changes in MPs over time-course of treatment predicted outcomes, the relative levels (initial vs. third month) of the four types of microparticles were analyzed. The differences in the four types of microparticles were designated as ΔEDAp-MPs, ΔEDAc-MPs, ΔPDAp-MPs and ΔPDAc-MPs, respectively.

Statistical analysis {#s4_5}
--------------------

Data were expressed as means ± standard deviation (SD). Continuous variables were analyzed by independent t tests and categorical variables were analyzed by the chi-square test. To determine outcomes, we compared levels of MPs three months after treatment with the initial levels. All variables were considered as risk factors with a *P* \< 0.10 in univariate analysis and were further analyzed by the multivariate logistic regression analysis to identify the independent factors that predict progressive disease. Receiver operating characteristic (ROC) curves were plotted and the area under the curve and CEA levels were compared for the four types of MPs. The cutoff value of MPs for predicting progressive disease in NSCLC patients was according to ROC curves. Results were presented as absolute numbers (percentage) or mean ± SD as well as medians, interquartile ranges and ranges for the various MP results. A two-tailed P value of less than 0.05 was considered statistically significant. Statistical analysis was performed using SPSS statistical software for Windows version 13 (SPSS for Windows, version 13; SPSS Inc., IL).
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